Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D81AQG
|
|||
| Drug Name |
AMG 890
|
|||
| Synonyms |
Olpasiran
Click to Show/Hide
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Cardiac fibrosis [ICD-11: DB98.8] | Phase 2 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Apolipoprotein A messenger RNA (LPA mRNA) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Plasminogen activating cascade | |||
| Pathway Interaction Database | amb2 Integrin signaling | |||
| Reactome | LDL-mediated lipid transport | |||
| WikiPathways | Lipid digestion, mobilization, and transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04270760) Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Amgen. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.